The Vascularized Composite Allotransplantation (VCA) Research Lab is leading research aimed at warding against rejection and reducing the number of medications patients have to take for the rest of their lives. They’re testing a protocol that involves treating the patient with antibodies on the day of transplant, followed by a donor bone marrow infusion several days later. This protocol would allow patients to be treated with low doses of a single maintenance drug after being transplanted.

Among the hundreds of predictive models developed for cardiovascular disease, less than one-tenth of 1% actually end up routinely used in clinical practice. CV-Ai2 uses data from clinical practice and analytic intelligence to solve clinical problems and create solutions that can be applied in real-world patient care.

Vascular research led by Rafael Tamargo, M.D., the Walter E. Dandy Professor of Neurosurgery, explores treatment of aneurysms, arteriovenous malformations, cavernous malformations, and arteriovenous fistulas of the brain and spinal cord. Basic science research has focused on endothelial cell-leukocyte interactions (inflammation) after subarachnoid hemorrhage and identifying drugs that might inhibit this inflammatory response as well as the narrowing of blood vessels.

Hypertension in children is a major cause of disease, including early onset heart disease. Up to 25% of children who are overweight or obese have hypertension (high blood pressure), and children with obesity are at greater risk for having other cardiovascular disease risk factors such as high cholesterol and diabetes. The ReNEW Clinic at The Johns Hopkins University provides an innovative multidisciplinary approach to the evaluation and treatment of obesity-related hypertension to help prevent and treat cardiovascular disease. This clinic is designed for children with elevated blood pressure (prehypertension and hypertension) and a BMI at or above the 85th percentile. Many children in this clinic are enrolled in a longitudinal registry to help researchers learn how to better care for children with multiple risk factors for heart disease.

Read more about the ReNEW clinic: Childhood Obesity: A Focus on Hypertension

The research program aims to advance cardiovascular biology and medicine by focusing on pluripotent stem cell-based modeling and therapy and by nurturing future leaders in regenerative medicine.

Our research is centered on the safety, efficacy and outcomes of PCI performed at hospitals without on-site cardiac surgery. Active projects: C-PORT Randomized Studies and Registries; New Jersey Angioplasty Demonstration Project; InCar-decision support tools for performance of PCI at hospitals without on-site cardiac surgery. For more information please visit Cport.org.

Research conducted in the Dhananjay Vaidya Lab focuses on the prevention of heart disease, with special emphasis on cardiometabolic risk factors, genetics in high-risk families, cardiovascular epidemiology, statistics and vascular biology. We also provide consultation on study design as well as plan and oversee data analyses for projects supported by the Center for Child and Community Health Research.

The Daniel Nyhan Lab studies vascular changes that accompany aging to determine the underlying causes and find ways to reverse the process. One goal of our research is to identify the factors that cause vascular stiffness. Our hope is that our work in vascular biology will lead to new ways to improve vascular compliance and thereby improve cardiovascular function and perioperative risk.

The Dara Kraitchman Laboratory focuses on non-invasive imaging and minimally invasive treatment of cardiovascular disease. Our laboratory is actively involved in developing new methods to image myocardial function and perfusion using MRI. Current research interests are aimed at determining the optimal timing and method of the administration of mesenchymal stem cells to regenerate infarcted myocardium using non-invasive MR fluoroscopic delivery and imaging. MRI and radiolabeling techniques include novel MR and radiotracer stem cell labeling methods to determine the location, quantity and biodistribution of stem cells after delivery as well as to noninvasively determine the efficacy of these therapies in acute myocardial infarction and peripheral arterial disease. Our other research focuses on the development of new animal models of human disease for noninvasive imaging studies and the development of promising new therapies in clinical trials for companion animals.

The Elizabeth Selvin Lab examines the intersection of epidemiology, clinical policy and public health policy. One of our key goals is to use the findings of epidemiologic research to inform the screening, diagnosis and treatment of diabetes, cardiovascular disease and kidney disease. Much of our work looks at biomarkers and diagnostics related to diabetes and diabetes complications. Our findings — linking hemoglobin A1c (HbA1c) to diabetic complications and identifying the role of A1c in diabetes diagnosis — have influenced clinical practice guidelines.